EUCTR2011-004168-30-DE进行中（未招募）1 期
A randomized phase II trial comparing pazopanib with doxorubicin as first line treatment in elderly patients with metastatic or advanced soft tissue sarcoma - EPAZ
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Signed written informed consent and willingness to comply with treatment and follow-up. Procedures conducted within 3 weeks as part of routine clinical management (e.g. blood count, imaging) and obtained prior to signing consent may be used for screening or baseline purposes if they are conducted as specified in the protocol
- •2.Male and female patients age = 60 years at day of inclusion
- •3.Histologically confirmed diagnosis of metastatic or advanced STS of intermediate or high grade with disease progression within 6 months prior to study inclusion:
- •Fibrosarcoma
- •Pleomorphic high grade sarcoma (malignant fibrous histiocytoma”)
- •Leiomyosarcoma
- •Liposarcoma
- •Malignant glomus tumor
- •Rhabdomyosarcoma, alveolar or pleomorphic (excluding embryonal)
- •Vascular sarcoma (epithelioid haemangioendothelioma, angiosarcoma)
- •Synovial sarcoma
- •Not otherwise specified (NOS)
- •Malignant peripheral nerve sheath tumors
- •Other types of sarcoma (not listed as ineligible), if approved by the study coordinator.
- •Excluding: Uncertain differentiation (epithelioid, alveolar soft part, clear cell, desmoplastic small round cell, malignant mesenchymoma, PEComa), chondrosarcoma, Ewing sarcoma/PNET, chordoma, malignant solitary fibrous tumors, embryonal rhabdomyosarcoma, osteosarcoma, gastro-intestinal stromal tumors, dermatofibrosarcoma protuberans, inflammatory myofibroblastic sarcoma (low-grade), neuroblastoma, malignant mesothelioma, and mixed mesodermal tumors of the uterus
- •(Study inclusion is based on local histopathological diagnosis).
- •4.ECOG performance status of 0-2 (Appendix D)
- •5.Evidence of progressive disease prior to start of treatment with measurable disease according to RECIST 1.1 (Appendix A)
- •6.Preferably archived tumor tissue of the most recent histology or, if not available, tumor block or 8 representative unstained sections on slides must be provided for all subjects for biomarker analysis within first month of treatment for central review
- •7.Adequate organ system function (see Table 1)
- •8.Male patients with female partners of childbearing potential must meet one of the following criteria:
- •At least 6 weeks after surgical sterilization by vasectomy with documentation of azoospermia
- •Correct use of two reliable contraception methods for 14 days before exposure to IMP, through the dosing period, and for at least 21 days after the last dose of IMP. This includes every combination of a hormonal contraceptive (such as oral, injection, transdermal patch, implant, cervical ring) or of an intrauterine device or system (IUD/IUS) with a barrier method (diaphragm, cervical cap, Lea contraceptive, femidom, or condom).
- •Complete sexual abstinence for 14 days before exposure to IMP, through the dosing period, and for at least 21 days after the last dose of IMP.
- •9.Women of childbearing potential must have a negative serum pregnancy test within 14 days of first dose of study treatment and agree to use effective contraception as defined below during the study and for 14 days following the last dose of investigational product.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 40
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 80
排除标准
- •1.Prior malignancy
- •Excluding: Subjects who have had another malignancy and have been disease-free for 2 years, or subjects with a history of completely resected non-melanomatous skin carcinoma, or successfully treated in situ carcinoma or incidental prostate cancer (tumor node metastasis (TNM) stage T1a or T1b) are eligible.
- •2.History or clinical evidence of CNS metastases
- •Excluding: Subjects who have previously-treated CNS metastases (radiotherapy, surgery ± radiotherapy, radiosurgery, or gamma knife) and who meet both of the following criteria: a) are asymptomatic and b) have no requirement for steroids or enzyme-inducing anticonvulsants 12 weeks prior to study inclusion. Screening with CNS imaging (CT or MRI) is required only if clinically indicated or if the subject has a history of CNS metastases.
- •3.Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding including but not limited to:
- •Active peptide ulcer disease
- •Known intraluminal metastatic lesion(s) with risk of bleeding
- •Inflammatory bowel disease (e.g. ulcerative colitis, Crohn’s disease) or other gastrointestinal conditions with increased risk of perforation
- •History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 28 days prior to beginning of study treatment
- •4.Clinically significant gastrointestinal abnormalities that may affect absorption of IMP including but not limited to:
- •Malabsorption syndrome
- •Major resection of the stomach or small bowels
- •5.Presence of uncontrolled infection
- •6.Corrected QT interval (QTc) > 480 msecs using Bazett’s formula
- •7.History of any one or more of the following cardiovascular conditions within the past 6 months:
- •Cardiac angioplasty or stenting
- •Myocardial infarction
- •Unstable angina
- •Coronary artery bypass graft surgery
- •Symptomatic peripheral vascular disease
- •8.Class III or IV congestive heart failure as defined by NYHA (Appendix E)
- •9.Poorly controlled hypertension (SBP of = 150 mmHg or DBP of =95 mmHg is acceptable provided that BP will be treated and monitored at least weekly. The goal is to attain controlled hypertension within 4 weeks of start of treatment, which is defined as grade =1 hypertension CTCAE Version 4.0; Appendix F)
- •Note: Initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry. BP must be re-assessed twice with an interval of at least 1h before start of IMP and should be =140/90 mmHg for a subject to be eligible for the study. However, BP of =150/95 mmHg is acceptable provided the above measures are employed
- •10.History of cerebrovascular accident including TIA, pulmonary embolism, or untreated DVT within the past 6 months
- •Note: Subjects with recent DVT who have been treated with therapeutic anti-coagulating agents for at least 6 weeks are eligible.
- •11.Major surgery or trauma within 28 days before first dose of IMP and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement are not considered to be major)
- •12.Evidence of active bleeding or bleeding diathesis
- •13.Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels
- •14.Hemoptysis in excess of 2.5 mL once within 8 weeks of first dose of IMP
- •15.Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with subject’s safety, provision of informed consent, or compliance to study procedures
- •16.Unable or unwilling to
研究者
相似试验
进行中（未招募）
1 期
Comparison of pazopanib with doxorubicin as first medication for elderly patients with severe soft tissue sarcomaEUCTR2011-004168-30-BEHannover Medical School120
进行中（未招募）
不适用
A phase I/II study of pazopanib in combination with temozolomide in patients with newly diagnosed glioblastoma multiforme after surgery and RT-CT (PAZOGLIO study)GlioblastomaEUCTR2014-001578-32-FRCENTRE ANTOINE LACASSAGNE51
进行中（未招募）
1 期
PASART 2soft tissue sarcomaMedDRA version: 19.0Level: HLTClassification code 10041298Term: Soft tissue sarcomas histology unspecifiedSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10024627Term: LiposarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10016632Term: FibrosarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10049067Term: Spindle cell sarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10024189Term: LeiomyosarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-004134-95-GBThe Netherlands Cancer Institute35
进行中（未招募）
不适用
Fase II onderzoek waarin de effectiviteit van 800 mg pazopanib in tabletvorm toegevoegd aan de standaard 25x bestraling wordt onderzocht, bij patiënten met weke delen tumoren in de armen of benen, de borstkas of buikwand en het hoofd/hals gebied (PASART-2)Phase II study to investigate the efficacy of adding 800 mg oral pazopanib to standard 25 x 2 Gy radiotherapy at patients with non-metastatic SArcoma patients lokalized in the extremities, trunk and chest wall or in the head and neck regionon-metastatic sarcoma patients localized in the extremities, trunk and chest wall or the head and neck regionMedDRA version: 18.1Level: PTClassification code 10039491Term: SarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: LLTClassification code 10039492Term: Sarcoma boneSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-004134-95-NLThe Netherlands Cancer Institute35
已完成
2 期
Phase II randomized clinical trial of Pazopanib alone and Pazopanib plus Gemcitabine in relapsed or metastatic soft tissue sarcomarelapsed or metastatic soft tissue sarcomaC49Malignant neoplasm of other connective and soft tissueDRKS00003139niversitätsklinikum Halle (Saale)90